{'fraction_non_alphanumeric': 0.014717906786590351, 'fraction_numerical': 0.0, 'mean_word_length': 5.915254237288136, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New Directions in Pharmacoeconomic Research: The Next Step

The United States Food and Drug Administration, managed care organizations, third-party payers, and national healthcare systems are engaged in reviewing pharmacoeconomic submissions from drug companies. Despite recommendations by various advisory committees on methods for conducting economic evaluations, differences in opinions among the producers of pharmacoeconomic information still exist on the appropriateness of the recommendations scientifically, as well as their suitability for intended users. We review the current state of the market for pharmacoeconomic information as well as the key methodologic issues facing those performing such analyses. While considerable progress has been made establishing rigorous methods for conducting economic evaluations, further progress can be made. This can be accomplished by convening the users and producers of this information. The goal of such a meeting would not be to develop a “one size fits all” standard but rather to maximize the scientific integrity of studies by providing broad technical guidance, modifications for different audiences, and applicability to a wide variety of healthcare interventions.